肺高血压和右心室:一种病理生理学的洞察力
Mehrshad Namazi1,2, Seyed Parsa Eftekhar1, Reza Mosaed1
1Trauma and Surgery Research Center, AJA University of Medical Sciences, Tehran, Iran.
Clinical Medicine Insights. Cardiology
|September 11, 2024
概括
肺高血压 (PH) 导致右心室 (RV) 压力过载,导致RV缩和衰竭,这是肺动脉高血压 (PAH) 死亡的主要原因. 氧化应激在RV衰竭的发展中起着关键作用.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 病理生理学 病理生理学
背景情况:
- 肺高血压 (PH) 是一种由高肺动脉压力定义的血管疾病.
- 持续的PH会导致右心室 (RV) 压力过载,RV缩,最终导致RV衰竭.
研究的目的:
- 阐明RV在PH中的结构和功能变化背后的机制.
- 要突出氧化应激在RV失效中的作用,这是PH的次要原因.
主要方法:
- 审查现有关于PH和RV失败的研究.
- 对拟议的病理生理机制的分析.
主要成果:
- 肺动脉功能衰竭是肺动脉高血压 (PAH) 死亡的主要原因.
- 拟议的机制包括细胞外重塑,缩,代谢转变,炎症,亡,自,内皮转移到介质细胞,神经激素失衡,毛细血管稀缺和缺血.
- 氧化应激在RV衰竭的发展中起着显著的作用.
结论:
- 了解这些机制的相互作用对于管理PH患者的RV衰竭至关重要.
- 针对氧化应激可能是一个关键的治疗策略.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
158
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
158
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Overview of Pulmonary Circulation
1.0K
The pulmonary circulation is a vital system in our body that acts as a bridge between the respiratory and cardiovascular systems. It serves as a transport network for deoxygenated blood from the heart to the lungs and then returns oxygen-rich blood back to the heart.
The process begins with the right ventricle of the heart pumping deoxygenated blood into the pulmonary trunk. This large vessel extends about 5 centimeters before splitting into the left and right pulmonary arteries. These arteries...
The process begins with the right ventricle of the heart pumping deoxygenated blood into the pulmonary trunk. This large vessel extends about 5 centimeters before splitting into the left and right pulmonary arteries. These arteries...
1.0K
Overview of Systemic and Pulmonary Circulation
3.7K
The systemic and pulmonary circuits are crucial components of the circulatory system, working together to transport blood between the heart, lungs, and the rest of the body. The process begins with pulmonary circulation, where deoxygenated blood is pumped from the right ventricle to the lungs via the pulmonary trunk and arteries. Upon reaching the lungs, the blood becomes oxygenated and returns to the heart, specifically to the left atrium, via the pulmonary veins.
The oxygenated blood is sent...
The oxygenated blood is sent...
3.7K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147


